BenevolentAI Investor Conference Presentation Deck

The Benevolent Platform™ is scientifically and commercially validated and has already delivered: Named 13 Platform-generated drug programmes Identified a leading COVID-19 treatment that is now FDA approved asset in Phase II 3 assets in pre-IND Successful multi-target collaboration with AstraZeneca further validates our approach with a total of 5 novel targets selected for AstraZeneca's portfolio +10 Exploratory stage programmes Well funded with key value inflection points in the near and medium term Benevolent 5

View entire presentation